Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02092298 · ClinicalTrials.gov registry record · Phase 2
Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Metastatic Gastric Cancer
A Phase 2 study of Gastrointestinal Cancer, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT02092298: Completed Phase 2 study of Gastrointestinal Cancer, sponsored by M.D. Anderson Cancer Center.
NCT02092298 is a Phase 2 study of Gastrointestinal Cancer that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 21 participants, below the 229-participant average among 49 other Gastrointestinal Cancer trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02092298, a Phase 2 study of Gastrointestinal Cancer, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to learn if hyperthermic intraperitoneal chemotherapy (HIPEC) will help to control the disease in patients with Stage 4 stomach or gastroesophageal cancer. The safety of this treatment will also be studied.
Primary Outcome
Primary objective of study is to assess overall survival (OS) in subjects with stage IV gastric cancer representing positive cytology or imaging occult carcinomatosis after laparoscopic hyperthermic intraperitoneal chemotherapy administration. Overall survival measured from time of laparoscopic HIPEC. Patterns of tumor recurrence and survival assessed by reviewing routine surveillance CT scans. Overall survival time estimated using the Kaplan-Meier method.
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Mitomycin C
- DRUG Sodium Thiosulfate
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2014-05-08 |
| Est. Completion | 2020-05-12 |
| Phase | Phase 2 |
What the finished NCT02092298 record still lists
NCT02092298 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 229-participant average among 49 other Gastrointestinal Cancer trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Gastrointestinal Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cisplatin is the first listed.
NCT02092298 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02092298 about?
NCT02092298 is a clinical study titled "Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Metastatic Gastric Cancer". The goal of this clinical research study is to learn if hyperthermic intraperitoneal chemotherapy (HIPEC) will help to control the disease in patients with Stage 4 stomach or gastroesophageal cancer. The safety of this treatment will also be studied.
What is the current status of trial NCT02092298?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2014-05-08. Estimated completion is 2020-05-12.
What conditions does trial NCT02092298 study?
This clinical trial studies the following conditions: Gastrointestinal Cancer.
What interventions are being tested in trial NCT02092298?
The interventions under investigation include: Cisplatin (DRUG), Mitomycin C (DRUG), Sodium Thiosulfate (DRUG).
Who is sponsoring clinical trial NCT02092298?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02092298 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastrointestinal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02092298's enrollment target sits among peer trials
21 43rd of 49 higher than 7 of 49 other Gastrointestinal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastrointestinal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study on the Effects of Exercise on Side Effects From Treatment for Gastrointestinal Cancers
RECRUITING · Phase 2
-
ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy
RECRUITING · Phase 2
-
sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)
RECRUITING · Phase 2
-
Avatrombopag vs. Placebo for CIT in GI Malignancies
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)
ACTIVE NOT RECRUITING · Phase 2
-
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI